Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment

BACKGROUND: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience relapses with a median progression-free survival of 12–18 months. There...

Descripción completa

Detalles Bibliográficos
Autores principales: Papa, Anselmo, Caruso, Davide, Strudel, Martina, Tomao, Silverio, Tomao, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024442/
https://www.ncbi.nlm.nih.gov/pubmed/27634150
http://dx.doi.org/10.1186/s12967-016-1027-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024442/
https://www.ncbi.nlm.nih.gov/pubmed/27634150
http://dx.doi.org/10.1186/s12967-016-1027-1

Ejemplares similares